Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.1, 2003-01, pp. : 87-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment

Current Drug Targets, Vol. 15, Iss. 6, 2014-06 ,pp. : 600-621

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes

By Augustyns Koen Van der Veken Pieter Senten Kristel Haemers Achiel

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 4, 2003-04 ,pp. : 499-510

Informa Healthcare

Access to resources Recommend Favorite

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

Current Medicinal Chemistry, Vol. 21, Iss. 35, 2014-01 ,pp. : 4013-4045

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

By Deacon Carolyn F Ahrén Bo Holst Jens J

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 9, 2004-09 ,pp. : 1091-1102

Informa Healthcare

Access to resources Recommend Favorite

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

Current Drug Targets, Vol. 10, Iss. 1, 2009-01 ,pp. : 71-87

Bentham Science Publishers

Access to resources Recommend Favorite